Exciting M&A news! @Genmab is set to acquire our portfolio company ProfoundBio for $1.8bn, expanding its oncology portfolio with promising antibody-drug conjugate technologies and clinical candidates, including the novel, next-gen Rina-S for #ovariancancer.
https://t.co/CsHU0ux8a0
Breaking #News: Genmab to broaden and strengthen its #oncology portfolio with the proposed acquisition of ProfoundBio, a biotechnology company focused on the development of novel #AntibodyDrugConjugate therapies.
Learn more at: https://t.co/Qr74ZbM2Mb
@JacobPlieth@Mykalt45 I might be the only person who was on the ADCETRIS approval team and worked at Stem. That name should have been reserved for me ;)
Is FRα the new Claudin18.2? Not quite, but the field suddenly features numerous competitors claiming superiority over $IMGN Elahere. Via @evaluatevantage from #ADC23 -> https://t.co/PqIFQla06g $STRO Profoundbio Elucida $ZYME
MIT Biotech Group Presents: Lecture 3 (Alliance Management) of the MIT Biotech Group’s Business Development Nanocourse on Nov 2nd, Tue, 5-6 PM EST.
Dr. Cathy Connelly (VP, Head of Alliance Management, Sanofi Genzyme) will be leading the lecture.
🛫 RT TO WIN 🛬
It’s Fly, Fly Away Friday and that means another chance to win flight vouchers for two from @AlaskaAir! RT RT RT! https://t.co/1jFZVRYEuL
@cispt2 Conversion of knowledge from one form/system to another. Like converting literature from one language to another. Some things are relevant (nouns, verbs), some are less relevant (articles), some just need understanding (word order). Drug developer. Am I close? :)
This is a tribute to the collaborative team of @slavovlab.
We did single-cell MS proteomics when influential colleagues said it's impossible. The key to overcoming skepticism was:
-- Releasing data & code ASAP.
-- Colleagues who reanalyzed our data & reproduced our methods.
@MAG2ART Nice! Makes me wonder how well mixed the cytoplasm is - all this time I thought it was mainly free diffusion with little mechanical agitation.
My question is to oncologists in general: why this difference in translating clinical trials results to clinical practice depending on subspecialties?
#lungcancer#breastcancer#ASCO21@OncoAlert
VCs are obsessed with moats and differentiators, but there's a $20b company whose differentiator for 5 years was "Uber, but with a large pink mustache zip tied on the cars."
#ASCO21 AMG 757 (tarlatamab) was effective in this pretreated #SCLC population. Confirmed RR 20% is impressive and this is still in escalation. Durability more impressive with median DOR 8.7m. These are encouraging data and look forward to more updates.